We have optimized a method for measuring total hydroxyproline (HYP) in urine by HPLC after release from urinary peptides by solid-phase hydrolysis on Dowex 50W x 8 ion-exchange resin. The HYP was derivatized with 4-chloro-7-nitrobenzo-2-oxa-1 ,3-diazole, and excess reagent was removed with the use of a 100-mg C18 BondElut cartridge. The HYP derivative was separated isocratically at 30 #{176}C on a 250 x 4.6 mm reversed-phase column containing 5-.an particles of Spherisorb S5 ODS-2, with S-carboxymethylcysteine as internal standard. Total assay time was 14 mm. The standard curve for the method was linear from the detection limit for HYP, 3.6 mol/L, to 10 mmol/L. The between-batch CV was <5.1% and the mean analytical recovery of HYP was 95% ± 1.4%. Comparison with a commercially available colorimetric method showed good correlation: y = 1.158x + 19.76 J.Lmol/L (S = 74, n = 120), but HPLC results were 15% higher, probably from incomplete hydrolysis with the colonmetric method. This method offers a considerable improvement in assay time, specificity, sensitivity, precision, and cost compared with the colorimetric method.
NBD-Cl because it reacts with HYP, a secondary amino acid, one order of magnitude more quickly than with primary amino acids (11, 12) , thus enhancing the specificity of the assay. Although the derivative is fluorescent, we decided to measure it with an ultraviolet detector because fluorescence detectors are less widely available.
Because >90% of urinary HYP is usually peptidebound (13, 14), measuring total urinary HYP requires hydrolysis before derivatization.
Although hydrochloric acid (6 mol/L) has commonly been used for hydrolysis (8, 12), we used cation-exchange resin because sulfonated resins in the hydrogen form are more effective than hydrochloric acid for peptide hydrolysis (15); in addition, several nonspecific chromogens and neutral compounds are removed by a wash step with the resin (16), and formation of humin is avoided. Previous methods for the assay of urinary HYP have presented a paucity of validation data. Our aim here was to provide a thorough evaluation of a simple and robust HPLC assay for routinely measuring total (i.e., free plus peptide-bound) urinary HYP in the clinical laboratory. (10 mmoIJL) was diluted with de-ionized water to give working standard solutions of 200, 500, and 1000 moIJL, which we stored in 300-FL aliquots at -20 #{176}C. A solution containing 100 /.LLof 10 mmol/L HYP solution, 8 mg of L-glutamic acid, 7 mg of L-serine, 10 mg of L-asparagine, and 4 mg of S-carboxymethylcysteine (8CMc; Sigma Chemical Co., Poole, Dorset, U.K.) in 10 mL of hydrochloric acid (0.2 mol/L) was used to check the performance of the analytical column. We dissolved 1 g of SCMC in 10 mL of hydrochloric acid (2 mol/L) as a stock internal-standard solution, then stored this at -20 #{176}C. Before the assay we prepared a working solution of internal standard by diluting the stock solution 55-fold with de-ioni.zed water. We dissolved glycyl-L-prolyl-L-HYP (Sigma Chemical Co.) in hydrochloric acid (10 mmol/L) to give a 7.24 mmolJL stock solution for analytical recovery experiments.
Materials and Methods
We suspended '-'-200 g of Dowex 50W x 8 strongly acidic cation-exchange resin (H form, 200-400 mesh; Sigma Chemical Co.) in two volumes of de-iomzed water, allowed the suspension to stand for 15 mm, then aspirated the supernate and any fines to waste. The resin was dried overnight at 56#{176}C, then stored. For hydrolysis, we freshly prepared a suspension of 300 mg of dry resin per milliliter of de-ionized water.
The derivatization reagent was prepared every seven weeks by dissolving 1 g of NBD-Cl (Aldrich Chemical Co., Ltd., Gillinghani, Dorset, U.K.) in 300 mL of methanol. We prepared potassium borate buffer solution (200 mmolJL) by dissolving 12.36 g of boric acid and 14.92 g of KC1 in 1 L of de-ionized water and adjusting the pH to 9.0 with NaOH solution (2 mol!L).
The chromatographic mobile phase was 70 mL of acetomtrile per liter of sodium acetate buffer (pH 6.0, 100 mmol/L). The Bond-Elut elution buffer was doublestrength mobile phase (140 mL of acetonitrile per liter of sodium acetate buffer, pH 6.0, 200 mmol/L). Both solutions were filtered through a 0.20-sm (pore-size) filter. Methanol and acetonitrile, HPLC-grade, were obtained from BDH Ltd., Poole, Dorset, U.K. All other chemicals were Analar grade from BDH Ltd.
Chromatographic System
The chromatographic system consisted of a Gilson 231 autosampler (Anachem, Luton, Beds., U.K.), a 30 x 4.6 mm Aquapore (5-pm particle-size) RP-300 guard column (Brownlee Labs., Santa Clara, CA), a 250 x 4.6 mm reversed-phase C18 column packed with 5-.m particles of Spherisorb S5 ODS-2 (Phase Separations Ltd., Queensbury, Clwyd, U.K.), a column heater (Model 7930; Jones Chromatography, Hengoed, Mid-Glamorgan, U.K.), a Spectroflow 400 pump and Spectroflow 783 detector (Kratos Analytical, Ramsay, NJ), and an integrator (Model SP4270; Spectra-Physics, San Jose, CA).
Procedures
Solid-phase hydrolysis.
The second voided urine after a 12-h overnight fast was collected (17) Excess derivatization reagent and byproducts were removed by passing 500 pL of the derivative through a 100-mg C18 Bond-Elut cartridge (Analytichem International, Harbor City, CA) that had been preconditioned with 1 mL of methanol followed by 1 mL of doubly distilled water. We then added 500 L of elution buffer. The cartridges were held in a 10-position suction manifold (Analytichem International), which assisted elution. The eluates were collected as one fraction, mixed, and an aliquot was immediately transferred into a brown glass autosampler vial. The C18 Bond-Elut cartridge can be reconditioned and re-used at least 10 times.
Chromatographic conditions.
We injected 20 L of the purified derivative onto the column. The flow rate was 0.9 mL/min, and the analytical column was heated to 30 #{176}C. Detection was at 495 nm, 0.05 A full scale; peak height was recorded. The calibration curve was obtained by plotting the HYP peak height relative to that for the internal standard (sCMc) vs the HYP concentration of the original sample (imolfL).
We assessed the within-batch and between-batch imprecision of the method by analyzing 20 times each six urine samples with HYP values covering the intended working range (50-1000 jmolJL). The between-batch analyses extended over a 10-week period.
We assessed the accuracy of the method by adding to a urine sample having an HYP concentration of "400 moWL increasing amounts of the tripeptide glycylprolyl-HYP to give final HYP concentrations of 150-850 p.mol/L, and then determining the analytical recovery. We repeated this with the same basal urine supplemented with free HYP to give added HYP concentrations of 50-750 mol/L. In evaluating analytical recovery, we assayed all samples in quadruplicate.
We evaluated linearity by diluting with de-ionized water two urine samples that contained >2000 mol of HYP per liter, and then assaying the diluted samples in quadruplicate.
One urine sample was from a patient with Paget's disease of the bone; the other was from a patient being treated with a gelatin-based plasma expander.
We investigated the effects on the assay of possible interfering substances three ways: (a) The aqueous dilution curves of three urine samples were compared for parallelism with that of an aqueous free HYP standard. We diluted the urine (by vol) 4:1,3:2,2:3, and five-, 10-, 20-, and 40-fold, and assayed the samples in duplicate. (b) We supplemented urine from an apparently healthy volunteer with various possible interferents at greatly increased concentrations, then compared the results with the basal urine value for any significant changes in apparent HYP concentration. All the urine samples were assayed in quadruplicate. (c) We investigated the presence of substances that could interfere with the internal standard by comparing the chromato- 
The sensitivity of the assay, i.e., change in absorbance per nanomole of HYP injected onto the column, was evaluated by measuring the HYP peak height for an aqueous HYP standard (0.267 nmol of HYP injected) in 10 assays.
To evaluate the stability of derivatized HYP and internal standard, we proceeded as follows: Five 200-L aliquots of a urine sample with an abnormal concentration of HYP (1500 tmol/L) were hydrolyzed on resin, derivatized, and pretreated by elution through C18 Bond-Elut cartridges. All the eluates were pooled. Aliquots (400 j.tL) of this pooled eluate were either left in the light or kept in the dark for 0, 10,20,40, and 60 min. After each interval we transferred the aliquot to an amber sample vial and assayed it by HPLC as soon as possible.
Drift during the chromatographic run was assessed by analyzing the same aqueous free HYP derivative (500 pmol/L) at the beginning and at the end of a full set of samples (54 vials), on 10 separate occasions.
We assessed total assay carryover by assaying in triplicate a urine sample with a high concentration of HYP (A1-A3), followed by a urine sample with a low concentration of HYP, also in triplicate (B1-B3), and applying the following formula (18):
Carryover in the chromatographic system was investigated by sampling a derivative with a very high concentration of HYP immediately followed by a mobile-phase blank, and confirming the absence of peaks during assay of the latter. This was done three times.
Before the start of each chromatographic run, a solution containing HYP, internal standard, asparagine, and glutamic acid was derivatized and injected onto the column to check the ability of the column to resolve closely eluting peaks. The capacity factor (k') and efficiency (N) of the HYP peak, and the selectivity (a) of the column with respect to HYP and the internal standard were recorded.
Method comparison. We investigated the correlation between results obtained with a solution-chemistry method involving resin hydrolysis (Hypronosticon kit; Organon Teknika, B.V., Boxtel, Holland) (16) and with the HPLC assay by assaying 120 patients' samples by both methods. Figure 1 shows typical chromatograms for the derivatives of (a) aqueous free HYP, (b) a "normal" urine sample, and (c) the same urine sample supplemented with free HYP. NBD-HYP was completely separated from other amino acid derivatives (ci. Figure id Typical chromatograms for urine samples from normal and abnormal subjects (Figure lb and /) show the satisfactory application of the chromatographic system for measuring total HYP in urine.
Results

Chromatography
Analytical Variables
Calibration and linearity. A linear calibration curve was obtained (Figure 2, top) , and results of the assay varied linearly with HYP concentration up to at least 10 mmoIIL in urine (Figure 2, bottom) .
Imprecision.
Data for assay reproducibility (withinand between-batch) for six urine specimens are shown in Table 1 . The CV was generally <5%. Use of an internal standard reduced within-batch assay imprecision.
Accuracy. The mean analytical recovery of HYP added to urine was 100% ± 1.4% (range 98-105%) for free HYP and 95% ± 1.4% (range 88-100%) for glycylprolyl-HYP.
Potential interferences.
We added to a urine sample from a healthy volunteer pathologically high concentrations of several potentially interfering substances: cose, urea, bilirubin, ammonium chloride, creatinine, and albumin. None produced a significant change (P >0.10) in the apparent concentration of HYP (87.3 cmolJL). The assay was also free from matrix effects, as demonstrated by the parallelism between the dilution curves for the aqueous free HYP standard and for urine, r = 0.9163 and 0.9180 (mean for the three urine curves), respectively.
The peak height of the internal standard was not affected by other peaks in any of the urine samples assayed. Derivative stability. The NBD-HYP peak height was highly stable (<2% decrease) over 60 mm when the derivatized sample was protected from the light. However, in samples exposed to laboratory lighting, the NBD-HYP peak height decreased by "40% over the same time interval.
Limit
The ratio of NBD-HYP:internal-standard peak heights increased <4% in 60 mm in the dark; in the light, it increased >15%. No significant drift was seen within runs (P >0.50). The mean HYP concentration measured at the end of the assay (54 samples) was 498.2 MmolJL (SD 11.2) compared with 500.0 mol/L at the start of the chromatographic run.
Cariyover. The total assay carryover was 0.76% for urine specimens with HYP concentrations of 980 and 180 p,molJL. Carryover for the chromatographic system alone was <0.01%, even from a urine sample with 2.40 mmol of HYP per liter. 
DIscussion
Having developed an HPLC separation system for total urinary HYP that is easy to perform with commonly available equipment and is capable of processing batches of 50 urine specimens (9), we evaluated the method thoroughly. NBD-Cl has been criticized as a derivatization reagent because of the photosensitivity of per hour). Correction with the internal-standard ratio for the decrease in signal in samples exposed to light was unsatisfactory, producing a significant upward trend (15%) within 60 mm, because the internal-standard derivative is less photosensitive than NBD-HYP. Therefore, we kept the derivative in the dark as much as possible after the reaction was stopped. The stability of the NBD-HYP:NBD--sCMc ratio and the effective halting of the derivatization reaction within the chromatographic run were proven by the insignificant drift (P >0.5).
The linearity of the calibration curve for aqueous free HYP (Figure 2, top) offers the possibility of single-point calibration, and the parallelism between the aqueous curve and urine dilutions demonstrated that aqueous standards can legitimately be used for assay calibration.
We used SCMC as an internal standard to correct for the technical and chemical manipulations involved in hydrolysis, sample clean-up, and derivatization. This internal standard did not co-elute with endogenous components of urine (Figure ii) or with any of the tested supplements listed. The precision of the assay was improved by use of the HYP:internal-standard peakheight ratio rather than HYP peak height alone (Table  1) .
We assessed the total assay recovery by supplementing a basal urine sample with glycyl-prolyl-HYP, which, with prolyl-HYP, reportedly accounts for as much as 75% of peptide-bound HYP in urine (22). Hydrolysis efficient enough to free HYP from the tripeptide should also release HYP from the dipeptide. The overall mean recovery relative to the internal standard of free HYP from urine containing various amounts of tripeptide was 95%. The mean recovery of free HYP at several concentrations in urine was 100%. The similarity between these recoveries is evidence of the efficiency and precision of the hydrolysis step.
Several substances, both endogenous and exogenous, that could possibly interfere with the assay failed to produce any significant effects. Urea and its conversion to ammonium chloride by acid hydrolysis, which have posed major interference problems for colorimetric methods (16), did not interfere with this HPLC assay.
Excellent linearity of results was demonstrated with a urine sample from a patient treated with gelatin infusion (Figure 2, bottom) . This ensured that we tested linearity with a pathophysiological urine containing metabolized HYP and peptides, such that the whole assay from hydrolysis to chromatography was tested on an extreme sample. The concentration above which linearity was lost, 10 mmol/L, greatly exceeded the concentration of total HYP expected from patients with abnormal collagen metabolism, including disorders such as Paget's disease and bone metastases.
Correlation data between HPLC methods and colorimetric methods have been produced elsewhere (5, 6). However, these data were based on small sample sizes (n <20). In comparing results for 120 urine samples with HYP concentrations covering the whole working range, we found that our HPLC method gave notably higher results ('-'45%) than those by the Hypronosticon method. Because the standardization of both assays was comparable, the sourceof the discrepancy is presumably in the hydrolysis stage. Although both methods use resin hydrolysis, the resins are different cation exchangers. In addition, the recommended hydrolysis time and temperature for the Hypronosticon method (16 h, 102 ±2#{176}C) are less than those used in our method, which gave 95% recovery of HYP from the tripeptide glycyl-prolyl-HYP.
The cost per test in terms of consumables, '-'$0.40 (the Bond-Elut cartridges may be re-used at least 10 times), represents a considerable saving over the Hypronosticon assay (-$3.00 per test). Routine use of this HPLC assay in our laboratory for more than six months has proven it to be both precise and reliable.
